CD8+ cytotoxic T cells kill tumor cells when they recognize an antigen that is presented by MHC class I. In ovarian cancer, tumor-infiltrating CD3+ and, more precisely, CD8+ T cells are associated with improved overall survival in advanced stage HGSC, as are high CD8/CD4 ratios (7–9). This evidence concerns the gene CD8A and neoplasm.